DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Natalizumab in multiple sclerosis: the second treatment revolution]

Author(s): Tourbah A

Affiliation(s): Service de neurologie et Faculte de Medecine, CHU de Reims, F-51092 Reims Cedex, France. ayman.tourbah@psl.aphp.fr

Publication date & source: 2008-01, Presse Med., 37(1 Pt 2):81-4. Epub 2007 Nov 26.

Publication type: English Abstract; Review

Natalizumab (Tysabri) is the first monoclonal antibody indicated for the treatment of active relapsing-remitting multiple sclerosis. Natalizumab is reserved for hospital use. Strict monitoring is necessary to detect side effects associated with the perfusion of the product, possible inefficacy of the treatment, and, more rarely, infectious complications, some of which (for example, progressive multifocal leukoencephalitis) are severe. Rigorous collection of efficacy and tolerance data will make it possible to assess the impact of this treatment on the natural history of multiple sclerosis.

Page last updated: 2008-08-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017